AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12505243 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment after disease progression or relapse
Number of subjects: 0
Study 9860474 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) 1000 mg/m2 per day for 5 days plus folinic acid 200 mg/m2 per day for 5 days
Number of subjects: 226
Study 9860474 — intervention group
Group type: COMPARATOR
Intervention: Liver resection only (Control)
Number of subjects: 226
Study 9860474 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion (HAI) of 5-FU
Number of subjects: 226
Study 7623373 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 Kcal/day diet (group A)
Number of subjects: 217
Study 7623373 — intervention group
Group type: COMPARATOR
Intervention: 2100 Kcal/day diet (group B)
Number of subjects: 217
Study 2375249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 200 mg
Number of subjects: 70
Study 2375249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 400 mg
Number of subjects: 70
Study 2375249 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 70
Study 2375249 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 70
Study 1062275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracain 4%
Number of subjects: 0
Study 1062275 — intervention group
Group type: COMPARATOR
Intervention: Xylocain 2%
Number of subjects: 0
Study 7303702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 93
Study 7303702 — intervention group
Group type: COMPARATOR
Intervention: Copper-T-200 Ag
Number of subjects: 93
Study 30994603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 30994603 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparins
Number of subjects: 0
Study 30994603 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 0
Study 29611892 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC901 (0.8 g capsules 3 times daily)
Number of subjects: 78
Study 29611892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 26348032 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills of Cognitive Therapy (SoCT-IO) rated by independent observers
Number of subjects: 80
Study 26348032 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills of Cognitive Therapy (SoCT-IO) ratings
Number of subjects: 80
Study 26348032 — intervention group
Group type: EXPERIMENTAL
Intervention: SoCT-IO ratings
Number of subjects: 80
Study 25272643 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous chloride dihydrate at concentrations of 200, 400, 600, and 800 microg, followed by intravenous administration of 99mTc at 30 min intervals in group one.
Number of subjects: 24
Study 25272643 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant concentration of 400 microg of Sn PYP, followed by administration of 99mTc at different time intervals (15, 30, 60, and 120 min) in group two.
Number of subjects: 24
Study 22403202 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching by nonclinician personnel
Number of subjects: 0
Study 19019903 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school physical activity interventions
Number of subjects: 0
Study 19019903 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school programmes
Number of subjects: 0
Study 18235411 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 18235411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thoracic irradiation and chemotherapy (platinum salts and etoposide)
Number of subjects: 0
Study 16298885 — intervention group
Group type: EXPERIMENTAL
Intervention: Free recall condition
Number of subjects: 40
Study 16298885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous cueing condition with SOA of 150 ms
Number of subjects: 40
Study 16298885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous cueing condition with SOA of 450 ms
Number of subjects: 40
Study 16298885 — intervention group
Group type: COMPARATOR
Intervention: Exogenous cueing condition
Number of subjects: 40
Study 12406041 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg t.i.d.)
Number of subjects: 369
Study 12406041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 10443654 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch
Number of subjects: 108
Study 10443654 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 108
Study 10443654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 7569587 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (oral or non-oral 17-beta estradiol at skeletally protective dose)
Number of subjects: 115
Study 7569587 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 115
Study 7569587 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 2161302 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg once daily) for 30 days in dermatophytosis
Number of subjects: 110
Study 2161302 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg once daily) for 15 days in pityriasis versicolor
Number of subjects: 110
Study 2161302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 2161302 — intervention group
Group type: EXPERIMENTAL
Intervention: Open phase treatment with itraconazole (100 mg once daily) for 15 days
Number of subjects: 110
Study 2161302 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 110
Study 505491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (1 gram every 4 hours up to 21 days)
Number of subjects: 64
Study 505491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31400046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose meloxicam (0.025 mg/kg/day PO)
Number of subjects: 51
Study 31400046 — intervention group
Group type: COMPARATOR
Intervention: Phenoxybenzamine and alprazolam
Number of subjects: 51
Study 29211013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 1 mg
Number of subjects: 100
Study 29211013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 0.5, 1, 2, or 4 mg (once daily for 35 days)
Number of subjects: 100
Study 29211013 — intervention group
Group type: COMPARATOR
Intervention: Cenerimod 25 mg
Number of subjects: 100
Study 29211013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod >1 mg
Number of subjects: 100
Study 29211013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod ≥10 mg
Number of subjects: 100
Study 25510210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (DX)
Number of subjects: 66
Study 25510210 — intervention group
Group type: COMPARATOR
Intervention: High-dosage betahistine (144mg/day)
Number of subjects: 66
Study 23448592 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 doses of mupirocin (twice daily for 5 days)
Number of subjects: 101
Study 23448592 — intervention group
Group type: COMPARATOR
Intervention: 6 doses of mupirocin (twice daily for 3 days or thrice daily for 2 days)
Number of subjects: 101
Study 21702402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 5 mg twice daily
Number of subjects: 201
Study 21702402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 5 mg four times daily
Number of subjects: 201
Study 21702402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 21702402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (both doses)
Number of subjects: 201
Study 19318991 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-month treatment for ADHD
Number of subjects: 436
Study 19318991 — intervention group
Group type: COMPARATOR
Intervention: MTA participants
Number of subjects: 436
Study 17520154 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% adenosine-containing dissolvable film, applied twice daily for three weeks
Number of subjects: 0
Study 17520154 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% adenosine-containing dissolvable film, applied twice daily for eight weeks
Number of subjects: 0
Study 17520154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 15876617 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease
Number of subjects: 21
Study 15876617 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly subjects
Number of subjects: 21
Study 12182690 — intervention group
Group type: EXPERIMENTAL
Intervention: ER felodipine 5 mg once daily for 2 weeks
Number of subjects: 35
Study 12182690 — intervention group
Group type: EXPERIMENTAL
Intervention: ER felodipine 10 mg/day for 2 weeks in non-responders
Number of subjects: 35
Study 12182690 — intervention group
Group type: EXPERIMENTAL
Intervention: ER felodipine 5 mg and 10 mg/day
Number of subjects: 35
Study 12182690 — intervention group
Group type: EXPERIMENTAL
Intervention: ER felodipine 5 to 10 mg/day
Number of subjects: 35
Study 9838913 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute drip infusion of granisetron (40 micrograms/kg with 100 ml saline)
Number of subjects: 20
Study 9838913 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second injection of granisetron (40 micrograms/kg with 10 ml saline)
Number of subjects: 20
Study 7528850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline (1 mg/kg as bolus followed by infusion of 15 micrograms/kg/min)
Number of subjects: 40
Study 7528850 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (2 mg/kg, followed by infusion of 30 micrograms/kg/min)
Number of subjects: 40
Study 7528850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline
Number of subjects: 40
Study 7528850 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 40
Study 7528850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study 2673619 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-bowel irrigation
Number of subjects: 10
Study 2673619 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal in sorbitol
Number of subjects: 10
Study 1251169 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid soap containing 0.04% phenylmercuric borate
Number of subjects: 128
Study 1251169 — intervention group
Group type: COMPARATOR
Intervention: Soap containing only hexachlorophene (Control)
Number of subjects: 128
Study 28195979 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Interval (SI) - 2 sets of 22 intervals of 10-second runs at 95% VIFT
Number of subjects: 18
Study 28195979 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Interval (LI) - 5 sets of 3-minute intervals at 85% VIFT
Number of subjects: 18
Study 28195979 — intervention group
Group type: COMPARATOR
Intervention: Both SI and LI
Number of subjects: 18
Study 28606845 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori screening and eradication
Number of subjects: 20011
Study 28606845 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20011
Study 25194639 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger rumination
Number of subjects: 120
Study 25194639 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive rumination
Number of subjects: 120
Study 25194639 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 120
Study 24024322 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao Pi‐II (100 mL, t.d.s., ante cibum)
Number of subjects: 180
Study 24024322 — intervention group
Group type: COMPARATOR
Intervention: Mosapride (5 mg, t.d.s., ante cibum)
Number of subjects: 180
Study 24024322 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao Pi‐II
Number of subjects: 180
Study 24024322 — intervention group
Group type: COMPARATOR
Intervention: Mosapride
Number of subjects: 180
Study 22166314 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with curative intent (272 patients, 82.9%)
Number of subjects: 328
Study 22166314 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoluminal ultrasound (EUS)
Number of subjects: 328
Study 22166314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Number of subjects: 328
Study 22166314 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative outcomes
Number of subjects: 328
Study 22166314 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 328
Study 22166314 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 328
Study 18202180 — intervention group
Group type: EXPERIMENTAL
Intervention: sCAX1 carrots
Number of subjects: 30
Study 18202180 — intervention group
Group type: COMPARATOR
Intervention: Control carrots
Number of subjects: 30
Study 16611279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg fasting at 7.00 AM
Number of subjects: 12
Study 16611279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg fasting at 7.00 PM
Number of subjects: 12
Study 16611279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg fed at 9.30 PM
Number of subjects: 12
Study 14523040 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IL-5 monoclonal antibody (mepolizumab)
Number of subjects: 24
Study 14523040 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 10962766 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session cognitive behavioral therapy (CBT)
Number of subjects: 279
Study 10962766 — intervention group
Group type: EXPERIMENTAL
Intervention: four‐session motivational enhancement therapy (MET)
Number of subjects: 279
Study 10962766 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session Twelve‐Step facilitation (TSF)
Number of subjects: 279
Study 8905281 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenation
Number of subjects: 50
Study 8905281 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenation
Number of subjects: 50
Study 8905281 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 1653883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (L) 10, 20, or 40 mg per day
Number of subjects: 91
Study 1653883 — intervention group
Group type: COMPARATOR
Intervention: Captopril (C) 25, 50, or 100 mg per day
Number of subjects: 91
Study 6626903 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hibiscrub shower
Number of subjects: 94
Study 6626903 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 94
Study 31516558 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Cast (FC)
Number of subjects: 72
Study 31516558 — intervention group
Group type: COMPARATOR
Intervention: Short Leg Cast (SLC)
Number of subjects: 72
Study 29767459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 8.4-33.6 g divided twice daily
Number of subjects: 304
Study 29767459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 304
Study 27599871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulcardine sulfate 200 mg
Number of subjects: 10
Study 27599871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulcardine sulfate 400 mg
Number of subjects: 10
Study 27599871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulcardine sulfate 800 mg
Number of subjects: 10
Study 27599871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulcardine sulfate 400 mg (fed)
Number of subjects: 10
Study 26181091 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 pills of study drug (150 microgram levonorgestrel and 30 microgram ethinyl estradiol combined OCPs)
Number of subjects: 32
Study 26181091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26181091 — intervention group
Group type: EXPERIMENTAL
Intervention: OCPs
Number of subjects: 32
Study 24018647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose management strategy aiming at plasma glucose level of 85 to 110 mg/dL using intravenous insulin
Number of subjects: 294
Study 24018647 — intervention group
Group type: COMPARATOR
Intervention: Conventional expectative glucose management
Number of subjects: 294
Study 24018647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose management strategy
Number of subjects: 294
Study 20919767 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI group
Number of subjects: 0
Study 20919767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18937673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus Wizard (phase A)
Number of subjects: 36
Study 18937673 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin dosing method (phase B)
Number of subjects: 36
Study 16144800 — intervention group
Group type: EXPERIMENTAL
Intervention: BE-8 infusion (anti-IL-6 monoclonal antibody)
Number of subjects: 219
Study 16144800 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan 220 mg/m2 plus dexamethasone with BE-8 infusion
Number of subjects: 219
Study 16144800 — intervention group
Group type: COMPARATOR
Intervention: Melphalan 200 mg/m2 and dexamethasone without BE-8 infusion
Number of subjects: 219
Study 12747286 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment combined with folic acid supplementation (1 mg/d)
Number of subjects: 17
Study 12747286 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) treatment combined with placebo
Number of subjects: 17
Study 12747286 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 17
Study 12747286 — intervention group
Group type: EXPERIMENTAL
Intervention: JIA patients
Number of subjects: 17
Study 11053073 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrocortisone
Number of subjects: 0
Study 11053073 — intervention group
Group type: COMPARATOR
Intervention: Higher doses or long acting triamcinolone
Number of subjects: 0
Study 8823699 — intervention group
Group type: EXPERIMENTAL
Intervention: ECO (combined cognitive/educational intervention)
Number of subjects: 131
Study 8823699 — intervention group
Group type: EXPERIMENTAL
Intervention: EDI (group education plus group discussion)
Number of subjects: 131
Study 8823699 — intervention group
Group type: COMPARATOR
Intervention: WLC (waiting list control)
Number of subjects: 131
Study 7955939 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg kg‐1)
Number of subjects: 10
Study 7955939 — intervention group
Group type: COMPARATOR
Intervention: No caffeine (control)
Number of subjects: 10
Study 3304372 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 15
Study 3304372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29856269 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS and CJM
Number of subjects: 144
Study 29856269 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS and CJM
Number of subjects: 144
Study 29856269 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS and Active CJM
Number of subjects: 144
Study 29856269 — intervention group
Group type: COMPARATOR
Intervention: Active TENS and Placebo CJM
Number of subjects: 144
Study 27267349 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (NovaBone) bone graft putty material
Number of subjects: 15
Study 27267349 — intervention group
Group type: COMPARATOR
Intervention: Platelet rich fibrin (PRF)
Number of subjects: 15
Study 24469238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year oral health fluoride varnish-oral health promotion intervention
Number of subjects: 1016
Study 24469238 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 1016
Study 22640000 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI combined with TCA 20%
Number of subjects: 39
Study 22640000 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540 nm fractional laser
Number of subjects: 39
Study 22640000 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alternating sessions of PCI and TCA 20% with 1540 nm fractional laser
Number of subjects: 39
Study 22846371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (300 mg/day) for 4 weeks
Number of subjects: 30
Study 20539245 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens (PHY)
Number of subjects: 21
Study 20539245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 21
Study 17658395 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification course (high-dose cytarabine and methotrexate)
Number of subjects: 482
Study 17658395 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 482
Study 17658395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid treatment protocol
Number of subjects: 482
Study 16254764 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Efficacy Questionnaire for Depression in Adolescents (SEQ-DA)
Number of subjects: 130
Study 15552071 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 18
Study 15552071 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 18
Study 10613649 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII (Recombinate) at a dose of 50 IU/kg
Number of subjects: 30
Study 10613649 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII (Recombinate) using concentrate standard
Number of subjects: 30
Study 8776185 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated circuit with low systemic heparinization (200 IU/kg)
Number of subjects: 101
Study 8776185 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit with higher systemic heparinization (300 IU/kg)
Number of subjects: 101
Study 8776185 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated group
Number of subjects: 101
Study 8776185 — intervention group
Group type: COMPARATOR
Intervention: Uncoated group
Number of subjects: 101
Study 1375679 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg oral dose)
Number of subjects: 20
Study 6330871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at night)
Number of subjects: 47
Study 6330871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 6330871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 47